Skip to content

Study on the mechanism of transcranial magnetic stimulation in the intervention of attention disorder after stroke

Study on the mechanism of transcranial magnetic stimulation in the intervention of attention disorder after stroke

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082383
Enrollment
Unknown
Registered
2024-03-27
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Sponsors

First Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosed as the first stroke, the diagnosis was in line with the diagnostic criteria for stroke revised at the 4th National Conference on Cerebrovascular Diseases in 1995, and the cerebral infarction in the right basal ganglia was confirmed by head CT or MRI scan, without serious speech dysfunction; (2) The Montreal Scale (MoCA=26 points) clearly assessed the existence of cognitive impairment; (3) The onset time was 1-6 months (30-180 days); (4) Aged 45-70 years old, right-handed; (5) The patient has good compliance and can cooperate with the evaluation and inspection of relevant scales; (6) Participate voluntarily and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) There are metal foreign bodies in the head, such as cochlear implants, metal dentures, etc., and cardiac pacemakers or other electronic devices implanted in the body; (2) epilepsy, increased intracranial pressure, active pulmonary tuberculosis, tumor; (3) Heart, lung, liver, kidney and other vital organ failure; (4) aphasia or severe cognitive impairment, unable to cooperate with assessment and treatment; (5) Pregnant or lactating women; (6) Subjects who have participated in other clinical studies in the past must meet the original clinical study group criteria or are currently participating in clinical studies of other drugs or medical devices; (7) Patients considered unsuitable for participation in this study by the investigator.

Design outcomes

Primary

MeasureTime frame
electroencephalogram;

Secondary

MeasureTime frame
Montreal Cognitive Assessment Scale score;Scoring of Self Care Ability Scale;Stroop score;n-back;functional near-infrared spectroscopy;Interleukin;immunoglobulin score;Digit span test score;Trail Making Test score;symbol digit modalities test score;Self-rating Depression Scale score;Self-rating Anxiety Scale score;Mini.mental state examination score;Hamilton Depression Scale score;Hamilton Anxiety Scale score;Fugl-Meyer Assessment;

Countries

China

Contacts

Public ContactWenyan Li

First Hospital of Shanxi Medical University

wen198102@163.com+86 138 3464 6011

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026